Every year world leaders come together to discuss the global economy at the World Economic Forum’s annual gathering in Davos Switzerland. This small town in the Alps has become the place where the smartest people on the planet come together to discuss solutions to the world’s economic problems and issues. It is not uncommon for various industries to establish a meeting place for people to come together for conversations.
For example, in 2019, the Canada Cannabis House hosted a three-day event for people in the cannabis industry to introduce themselves and talk about business with people who were unfamiliar with the industry. This year, Davos is also hosting events around blockchain and cryptocurrency cementing its reputation as a place that encourages forward-thinking outlooks.
In addition to standard topics around climate change and the economy, healthcare is a frequent subject, This year there is a big focus on psychedelic plant medicine and how numerous studies have shown it could be a game-changer for mental health treatments.
One thing that is new this year for Davos is that the main event, the World Economic Forum, was pushed back from its traditional January date to May due to the pandemic. Another new feature will be the inaugural Medical Psychedelic Series which hopes to help shape the future of mental health. The inaugural week-long series will take place from May 21-26, 2022, at the Medical Psychedelics House of Davos located on the main Promenade. It will feature the world’s most prominent psychedelic industry leaders, drug development experts, clinicians, nonprofit organizations, advocates, and influencers. The majority of conversations at the Medical Psychedelics House of Davos will focus on FDA approval for these compounds and their associated therapeutic potential, policy, safety and efficacy, biocultural preservation, drug development pipelines, and patient access.
“This is a one-of-a-kind opportunity for the medical psychedelics ecosystem to share the breakthroughs in psychedelic therapeutics for the first time with world leaders,” says Marik Hazan, CEO of Energia Holdings Incorporated.
“We want to spark conversations about the high unmet need in mental health, the future of FDA approved psychedelic-assisted therapy, provide a platform for establishing meaningful relationships and partnerships, and build trust with the global community,” added Maria Velkova, managing partner of Tabula Rasa Ventures.
Hosted by Energia Holdings Incorporated, the series includes educational talks and panels featuring some of the best-known figures in the psychedelic space, including acclaimed author and psychedelic medicine advocate Deepak Chopra; TV personality and advocate Jason Silva; countess of Wemyss and March, and nonprofit leader Amanda Fielding; psychedelic researcher David Nichols, Ph.D.; Endowed Professor & Vice Chair of Psychiatry, Icahn School of Medicine at Mount Sinai Rachel Yehuda, Ph.D. and many more.
As the COVID-19 pandemic laid bare, mental health is one of the largest underserved areas in the medical community. With few solutions in sight, there is a growing body of evidence that suggests that psychedelic-assisted therapy could provide a breakthrough in treating countless mental health ailments, such as depression, substance abuse disorders, and PTSD.
At Davos 2022, This Medical Psychedelics Series Will Be the Global Platform for Where Select Attendees Will:
Learn from leading experts in the medical psychedelics industry who are setting the narrative for both mental health and psychedelic therapeutics on the global stage in front of world leaders.
Experience sessions curated to engage all six senses and give an unforgettable heart-opening, mind-stimulating, experience of human connection through sound meditation, breathwork, and conscious leadership workshops.
Connect with psychedelic entrepreneurs, researchers, policy makers, and nonprofit leaders and some of the world’s most innovative psychedelic organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS), Maya Health, Compass Pathways, Imperial College London, and many others.